Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 27% Improvement Relative Risk Hospitalization 6% Hospitalization (b) 39% Extended ER observation.. -14% primary Extended ER observa.. (b) 12% ER visit 31% ER visit (b) 26% Viral clearance 1% Reis et al. NCT04727424 TOGETHER Metformin RCT EARLY Is early treatment with metformin beneficial for COVID-19? Double-blind RCT 421 patients in Brazil Lower mortality (p=0.53) and progression (p=0.48), not stat. sig. Reis et al., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2021.100142 Favors metformin Favors control
Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial
Reis et al., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2021.100142 (date from earlier preprint), TOGETHER, NCT04727424 (history)
Reis et al., Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with.., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2021.100142 (date from earlier preprint), TOGETHER, NCT04727424
Aug 2021   Source   PDF  
  All Studies   Meta
Data for the primary outcome in this trial appears to be impossible []. For example, considering the metformin arm and the ITT population: 24 were hospitalized and 8 had an ER visit (tables S2/S3), therefore the number for combined ER or hospitalization must be between 24 and 32. However, authors
report 34 events for ER/hospitalization.
RCT with 215 patients treated with metformin and 203 controls, showing no significant difference with treatment.
For multiple major issues with this trial see [, (B)].
The hospitalization risk for off-protocol patients was several times higher in both arms, resulting in Simpson's paradox when combining per-protocol and off-protocol patients [].
750mg twice daily for 10 days.
Although the 27% lower mortality is not statistically significant, it is consistent with the significant 32% lower mortality [27‑37%] from meta analysis of the 49 mortality results to date.
risk of death, 26.6% lower, RR 0.73, p = 0.53, treatment 7 of 215 (3.3%), control 9 of 203 (4.4%), NNT 85, day 28.
risk of hospitalization, 5.6% lower, RR 0.94, p = 0.88, treatment 24 of 215 (11.2%), control 24 of 203 (11.8%), NNT 152, ITT.
risk of hospitalization, 39.1% lower, RR 0.61, p = 0.28, treatment 8 of 168 (4.8%), control 14 of 179 (7.8%), NNT 33, PP.
risk of extended ER observation or hospitalization, 14.0% higher, RR 1.14, p = 0.58, treatment 34 of 215 (15.8%), control 28 of 203 (13.8%), ITT, primary outcome.
risk of extended ER observation or hospitalization, 12.0% lower, RR 0.88, p = 0.72, treatment 14 of 168 (8.3%), control 17 of 179 (9.5%), NNT 86, PP.
risk of ER visit, 31.0% lower, RR 0.69, p = 0.48, treatment 8 of 216 (3.7%), control 11 of 205 (5.4%), NNT 60, ITT.
risk of ER visit, 25.9% lower, RR 0.74, p = 0.62, treatment 7 of 171 (4.1%), control 10 of 181 (5.5%), NNT 70, PP.
risk of no viral clearance, 1.0% lower, RR 0.99, p = 0.85, treatment 215, control 203, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Reis et al., 31 Aug 2021, Double Blind Randomized Controlled Trial, Brazil, peer-reviewed, 23 authors, impossible data, see notes, trial NCT04727424 (history) (TOGETHER).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial
Gilmar Reis, Eduardo Augusto, Moreira Santos, Silva, Daniela Carla Medeiros, Lehana Thabane, Aline Cruz Milagres, Thiago Santiago Ferreira, Castilho Vitor Quirino, Santos, Adhemar Dias, Figueiredo Neto, Eduardo Diniz Callegari, Leonardo Cançado, Monteiro Savassi, Maria Izabel Campos, Luciene Barra, Rosemary Oliveira, Ofir Harari, Holly Bailey, Jamie I Forrest, Alla Glushchenko, Sheila Sprague, Paula Mckay, Craig R Rayner, Hinda Ruton, Gordon H Guyatt, Edward J Mills
Background Observational studies have postulated a therapeutic role of metformin in treating COVID-19. We conducted an adaptive platform clinical trial to determine whether metformin is an effective treatment for high-risk patients with early COVID-19 in an outpatient setting. Methods The TOGETHER Trial is a placebo-controled, randomized, platform clinical trial conducted in Brazil. Eligible participants were symptomatic adults with a positive antigen test for SARS-CoV-2. We enroled eligible patients over the age of 50 years or with a known risk factor for disease severity. Patients were randomly assigned to receive either placebo or metformin (750 mg twice daily for 10 days or placebo, twice daily for 10 days). The primary outcome was hospitalization defined as either retention in a COVID-19 emergency setting for > 6 h or transfer to tertiary hospital due to COVID-19 at 28 days post randomization. Secondary outcomes included viral clearance at day 7, time to hospitalization, mortality, and adverse drug reactions. We used a Bayesian framework to determine probability of success of the intervention compared to placebo.
Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j. lana.2021.100142.
Bramante, Ingraham, Murray, Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis, Lancet Healthy Longev
Chen, Guo, Qiu, Zhang, Deng et al., Immunomodulatory and antiviral activity of metformin and its potential implications in treating coronavirus disease 2019 and lung injury, Front Immunol
Cheng, Liu, Li, Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes, Cell Metab
Dimairo, Pallmann, Wason, The adaptive designs CON-SORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design, BMJ
Forrest, Rayner, Park, Mills, Early treatment of COVID-19 disease: a missed opportunity, Infect Dis Ther
Goodman, Stopping at nothing? Some dilemmas of data monitoring in clinical trials, Ann Intern Med
Matsiukevich, Piraino, Lahni, Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock, Biochim Biophys Acta Mol Basis Dis
Park, Harari, Dron, Lester, Thorlund et al., An overview of platform trials with a checklist for clinical readers, J Clin Epidemiol
Park, Lee, Park, Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients, World J Gastroenterol
Quan, Zhang, Wei, Fang, Gender-related different effects of a combined therapy of exenatide and metformin on overweight or obesity patients with type 2 diabetes mellitus, J Diabetes Complic
Reis, Silva, Silva, A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol, Gates Open Res
Reis, Silva, Silva, Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial, JAMA Netw Open
Thorlund, Dron, Park, Hsu, Forrest et al., A real-time dashboard of clinical trials for COVID-19, Lancet Digit Health
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop